This study focuses on cases of NSCLC with primary resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) therapy and highlights the failure of TKIs as effective treatments. This evidence concerns the gene EGFR and non-small cell lung carcinoma.